Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation
Top Cited Papers
Open Access
- 21 October 2013
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (45) , 18256-18261
- https://doi.org/10.1073/pnas.1314351110
Abstract
We compare the antigenicity and conformation of soluble, cleaved vs. uncleaved envelope glycoprotein (Env gp)140 trimers from the subtype A HIV type 1 (HIV-1) strain BG505. The impact of gp120–gp41 cleavage on trimer structure, in the presence or absence of trimer-stabilizing modifications (i.e., a gp120–gp41 disulfide bond and an I559P gp41 change, together designated SOSIP), was assessed. Without SOSIP changes, cleaved trimers disintegrate into their gp120 and gp41-ectodomain (gp41ECTO) components; when only the disulfide bond is present, they dissociate into gp140 monomers. Uncleaved gp140s remain trimeric whether SOSIP substitutions are present or not. However, negative-stain electron microscopy reveals that only cleaved trimers form homogeneous structures resembling native Env spikes on virus particles. In contrast, uncleaved trimers are highly heterogeneous, adopting a variety of irregular shapes, many of which appear to be gp120 subunits dangling from a central core that is presumably a trimeric form of gp41ECTO. Antigenicity studies with neutralizing and nonneutralizing antibodies are consistent with the EM images; cleaved, SOSIP-stabilized trimers express quaternary structure-dependent epitopes, whereas uncleaved trimers expose nonneutralizing gp120 and gp41ECTO epitopes that are occluded on cleaved trimers. These findings have adverse implications for using soluble, uncleaved trimers for structural studies, and the rationale for testing uncleaved trimers as vaccine candidates also needs to be reevaluated. Significance Trimeric forms of HIV-1 envelope glycoproteins are being used for structural and vaccine studies. The most common way to make these proteins is to eliminate the cleavage site between the glycoprotein (gp)120 and gp41 subunits. We show that doing so creates trimers that adopt irregular, nonnative configurations. Cleaved, stabilized trimers, in contrast, resemble the native spikes on the HIV-1 virus. Our findings will help structural and vaccine programs by showing how to make native-like trimers. The rationale for vaccine trials based on the use of uncleaved gp140 trimers should be reevaluated.Keywords
This publication has 44 references indexed in Scilit:
- A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing AntibodiesPLoS Pathogens, 2013
- Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding GlycansPLoS Pathogens, 2013
- Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9Proceedings of the National Academy of Sciences, 2013
- HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120Proceedings of the National Academy of Sciences, 2012
- An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 SerumJournal of Virology, 2011
- HIV-1 Envelope Glycoprotein Biosynthesis, Trafficking, and IncorporationJournal of Molecular Biology, 2011
- A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human VolunteersThe Journal of Infectious Diseases, 2011
- Rational antibody-based HIV-1 vaccine design: current approaches and future directionsCurrent Opinion in Immunology, 2010
- Molecular architecture of native HIV-1 gp120 trimersNature, 2008
- Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigmRetrovirology, 2008